Back

Prescribing SGLT2 inhibitors in acute heart failure: considerations for dysglycemia status, heart failure phenotype, and kidney function

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in interventional cardiology and pharmacology 2 Antidiabetic Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Aiganym Amanova

Aktobe (Kazakhstan)

6 More presentations in this session

Presentation thumbnail
Challenging the norm: the use of sublingual nitroglycerin in patients with severe aortic stenosis undergoing cardiac CT
Doctor A. Silva (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Age differences in prescribing guideline-directed medical treatment in heart failure with mildly reduced and reduced ejection fraction
Doctor V. Lopes (Coimbra, PT)
Abstract Slides Video
Presentation thumbnail
Adherence to the guideline-directed medical therapy in chronic heart failure: insight from a University Hospital
Doctor M. Assamti (Oujda, MA)
Abstract Slides Video
Presentation thumbnail
Use of SGLT2 inhibitors in real life: predicting left ventricular reverse remodelling.
Doctor V. De Simone (Legnago, IT)
Abstract Slides Video
Presentation thumbnail
Real world registry of use of SGLT2i in patients with HFrEF followed in a non-tertiary hospital.
Mr V. Martinez Mateo (Alcazar de San Juan, ES)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in interventional cardiology and pharmacology 2

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Cardiovascular diseases and type 2 diabetes mellitus: high heart failure risk and low rate contraindications to SGLT2i
thumbnail
Congress Presentation
Short-term effects of SGLT2 inhibitors on myocardial extracellular volume, left ventricular function and inflammation in patients with HFpEF and diabetes mellitus
thumbnail
Congress Presentation
Initiation of sodium-glucose co-transporter-2 inhibitors in patients with heart failure in the acute medical setting

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources